Ethics code: IR.IAU.DAMGHAN.REC.1399.003
Clinical trials code: IRCT20151228025732N62
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shokravian M, Miladi-Gorji H, Shajiee H, Ghorbani R, Mazinani M. Effect of Raha Herbal Syrup on Craving Severity and Serum Cortisol Level of Men With Opiate Use Disorder Under Opium Tincture Maintenance Therapy: A Randomized Clinical Trial. Qom Univ Med Sci J 2024; 18 : 2786.1
URL: http://journal.muq.ac.ir/article-1-3625-en.html
URL: http://journal.muq.ac.ir/article-1-3625-en.html
1- Department of Biology, Faculty of Science, Damghan Branch, Islamic Azad University, Damghan, Iran.
2- Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. ,miladi331@yahoo.com
3- Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran.
4- Sina Addiction Treatment Center, Semnan, Iran.
2- Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. ,
3- Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran.
4- Sina Addiction Treatment Center, Semnan, Iran.
Abstract: (539 Views)
Background and Objectives: This study aims to examine the effect of Raha herbal syrup on the craving severity and changes in serum cortisol levels of men with opioid use disorder (OUD) under the opium tincture (OT) maintenance therapy.
Methods: This is a randomized controlled clinical trial with a pre-test/post-test design. Participants were 62 men with OUD under OT maintenance therapy who were physically dependent on opioid and were using it for 4-6 years. They were randomly divided into two groups of OT (n=30), and OT+Raha syrup (n=32). Both groups completed the desire for drug questionnaire (DDQ) before and after treatment. Venous blood samples were taken from patients after 8 hours of fasting before and after the treatment to measure serum cortisol levels.
Results: After intervention, the momentary assessment showed that craving intensity score in the OT+ Raha syrup group decreased by 8.72, while the OT group showed a decrease by 1.77. This reduction in mean score was significantly different between the two groups (P<0.001). Moreover, after the intervention, the mean serum cortisol level in the OT+Raha syrup group decreased by 1.09, while the OT group showed a decrease by 0.01, but it was significantly different.
Conclusion: The use of OT for maintenance treatment along with Raha herbal syrup can be useful for reducing craving for opioid in men with OUD during the abstinence period. Therefore, the simultaneous use of Raha syrup with OT may be beneficial for the management of abstinence from opioid.
Methods: This is a randomized controlled clinical trial with a pre-test/post-test design. Participants were 62 men with OUD under OT maintenance therapy who were physically dependent on opioid and were using it for 4-6 years. They were randomly divided into two groups of OT (n=30), and OT+Raha syrup (n=32). Both groups completed the desire for drug questionnaire (DDQ) before and after treatment. Venous blood samples were taken from patients after 8 hours of fasting before and after the treatment to measure serum cortisol levels.
Results: After intervention, the momentary assessment showed that craving intensity score in the OT+ Raha syrup group decreased by 8.72, while the OT group showed a decrease by 1.77. This reduction in mean score was significantly different between the two groups (P<0.001). Moreover, after the intervention, the mean serum cortisol level in the OT+Raha syrup group decreased by 1.09, while the OT group showed a decrease by 0.01, but it was significantly different.
Conclusion: The use of OT for maintenance treatment along with Raha herbal syrup can be useful for reducing craving for opioid in men with OUD during the abstinence period. Therefore, the simultaneous use of Raha syrup with OT may be beneficial for the management of abstinence from opioid.
Article number: 2786.1
Type of Study: Original Article |
Subject:
فیزیولوژی
Received: 2022/12/9 | Accepted: 2023/10/25 | Published: 2024/04/29
Received: 2022/12/9 | Accepted: 2023/10/25 | Published: 2024/04/29
References
1. Bao G, Kang L, Li H, Li Y, Pu L, Xia P, et al. Morphine and heroin differentially modulate in vivo hippocampal LTP in opiate-dependent rat. Neuropsychopharmacology. 2007; 32(8):1738-49. [DOI:10.1038/sj.npp.1301308] [PMID]
2. Eagle A. Masraf BA, Robison A. Chapter 3 - Transcriptional and epigenetic regulation of reward circuitry in drug addiction. In: Torregrossa M, editor. Neural mechanisms of addiction. Amsterdam: Elsevier; 2019. [DOI:10.1016/B978-0-12-812202-0.00003-8]
3. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: The role of reward-related learning and memory. Annu Rev Neurosci. 2006; 29:565-98. [DOI:10.1146/annurev.neuro.29.051605.113009] [PMID]
4. Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol. 2005; 5(1):9-19. [DOI:10.1016/j.coph.2004.11.001] [PMID]
5. Bowen MT, Neumann ID. Rebalancing the addicted brain: Oxytocin interference with the neural substrates of addiction. Trends Neurosci. 2017; 40(12):691-708. [DOI:10.1016/j.tins.2017.10.003] [PMID]
6. Méndez M, Morales-Mulia M. Role of mu and delta opioid receptors in alcohol drinking behaviour. Curr Drug Abuse Rev. 2008; 1(2):239-52. [DOI:10.2174/1874473710801020239] [PMID]
7. Drolet G, Dumont EC, Gosselin I, Kinkead R, Laforest S, Trottier JF. Role of endogenous opioid system in the regulation of the stress response. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25(4):729-41. [DOI:10.1016/S0278-5846(01)00161-0] [PMID]
8. Li SX, Li J, Epstein DH, Zhang XY, Kosten TR, Lu L. Serum cortisol secretion during heroin abstinence is elevated only nocturnally. Am J Drug Alcohol Abuse. 2008; 34(3):321-8. [DOI:10.1080/00952990802013664] [PMID]
9. Robinson TE, Berridge KC. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993; 18(3):247-91. [DOI:10.1016/0165-0173(93)90013-P] [PMID]
10. Paulson PE, Camp DM, Robinson TE. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology (Berl). 1991; 103(4):480-92. [DOI:10.1007/BF02244248] [PMID]
11. Koob GF, Schulkin J. Addiction and stress: An allostatic view. Neurosci Biobehav Rev. 2019; 106:245-62. [DOI:10.1016/j.neubiorev.2018.09.008] [PMID]
12. Nikoo M, Nikoo N, Anbardan SJ, Amiri A, Vogel M, Choi F, et al. Tincture of opium for treating opioid dependence: a systematic review of safety and efficacy. Addiction. 2017; 112(3):415-29. [DOI:10.1111/add.13628] [PMID]
13. Jittiwutikarn J, Ali R, White JM, Bochner F, Somogyi AA, Foster DJ. Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. Br J Clin Pharmacol. 2004; 58(5):536-41. [DOI:10.1111/j.1365-2125.2004.02209.x] [PMID]
14. Seiri L, Mokri A, Dezhakam H, Noroozi A. Using tincture of opium for treatment of opiate abusers in Iran. Drug Alcohol Depend. 2014; 140:e200. [DOI:10.1016/j.drugalcdep.2014.02.558]
15. He M, Zhang H, Tang J, Tang Z, Yang D, Chen X, et al. A comparative study of buprenorphine plus naloxon vs opium tincture in the detoxification treatment of heroin dependence. Chin J Clin Psychol. 1996; 4(1):10-5. [Link]
16. Talebi Keyasari F, Miladi Gorji H. [Effect of medicinal plants in the treatment of opium addiction Review of laboratory studies (Persian)]. North Khorasan Univ Med Sci. 2013; 4(5):157-65. [DOI:10.29252/jnkums.4.5.S5.157]
17. Liyaghat Z, Baha AB, Khoshnoud M, Liyaghat M. [Survey of the effects of Raha® and Berberin medicine in toxic and sub toxic doses compare with clonidine medicine on reducing symptoms of morphine withdrawal in Syrian mice (Persian)]. Zahedan J Res Med Sci. 2010; 12(3):12-8. [Link]
18. Gorji HM, Rashidy-Pour A, Fathollahi Y, Semnanian S, Akhavan MM. [Effects of voluntary exercise on severity of naloxone precipitated morphine withdrawal signs in rats (Persian)]. Koomesh. 2010; 12(1):86-92. [link]
19. Ebrahimie M, Bahmani M, Shirzad H, Rafieian-Kopaei M, Saki K. A review study on the effect of Iranian herbal medicines on Opioid Withdrawal syndrome. J Evid Based Complementary Altern Med. 2015; 20(4):302-9. [DOI:10.1177/2156587215577896] [PMID]
20. Moloudizargari M, Mikaili P, Aghajanshakeri S, Asghari MH, Shayegh J. Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids. Pharmacogn Rev. 2013; 7(14):199-212. [DOI:10.4103/0973-7847.120524] [PMID]
21. Lee B, Shim I, Lee H, Hahm DH. Berberine alleviates symptoms of anxiety by enhancing dopamine expression in rats with post-traumatic stress disorder. Korean J Physiol Pharmacol. 2018; 22(2):183-92. [DOI:10.4196/kjpp.2018.22.2.183] [PMID]
22. Tao R, Auerbach SB. GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther. 2002; 303(2):704-10. [DOI:10.1124/jpet.102.038133] [PMID]
23. Tao R, Ma Z, Auerbach SB. Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine. J Pharmacol Exp Ther. 1998; 286(1):481-8. [PMID]
24. Franken IH, Hendriksa VM, van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav. 2002; 27(5):675-85. [DOI:10.1016/S0306-4603(01)00201-5] [PMID]
25. Hassani-Abharian P, Mokri A, Ganjgahi H, Oghabian MA, Ekhtiari H. Validation for Persian versions of "Desire for Drug Questionnaire" and "Obsessive Compulsive Drug Use Scale" in heroin dependents. Arch Iran Med. 2016; 19(9):659-65. [Link] [PMID]
26. Auriacombe M, Grabot D, Daulouède JP, Vergnolle JP, O'Brien C, Tignol J. A naturalistic follow-up study of French-speaking opiate-maintained heroin-addicted patients: Effect on biopsychosocial status. J Subst Abuse Treat. 1994; 11(6):565-8. [DOI:10.1016/0740-5472(94)90008-6] [PMID]
27. Somogyi AA, Larsen M, Abadi RM, Jittiwutikarn J, Ali R, White JM. Flexible dosing of tincture of opium in the management of opioid withdrawal: Pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 2008; 66(5):640-7. [DOI:10.1111/j.1365-2125.2008.03277.x] [PMID]
28. Kulkarni SK, Dhir A. Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res. 2010; 24(3):317-24. [DOI:10.1002/ptr.2968] [PMID]
29. Yoo JH, Yang EM, Cho JH, Lee JH, Jeong SM, Nah SY, et al. Inhibitory effects of berberine against morphine-induced locomotor sensitization and analgesic tolerance in mice. Neuroscience. 2006; 142(4):953-61. [DOI:10.1016/j.neuroscience.2006.07.008] [PMID]
30. Bhutada P, Mundhada Y, Bansod K, Dixit P, Umathe S, Mundhada D. Anticonvulsant activity of berberine, an isoquinoline alkaloid in mice. Epilepsy Behav. 2010; 18(3):207-10. [DOI:10.1016/j.yebeh.2010.03.007] [PMID]
31. Lee B, Sur B, Yeom M, Shim I, Lee H, Hahm DH. Effect of berberine on depression- and anxiety-like behaviors and activation of the noradrenergic system induced by development of morphine dependence in rats. Korean J Physiol Pharmacol. 2012; 16(6):379-86. [DOI:10.4196/kjpp.2012.16.6.379] [PMID]
32. Gomaa A, Hashem T, Mohamed M, Ashry E. Matricaria chamomilla extract inhibits both development of morphine dependence and expression of Abstinence syndrome in rats. J Pharmacol Sci. 2003; 92(1):50-5. [DOI:10.1254/jphs.92.50] [PMID]
33. Zhang G, Wu X, Zhang YM, Liu H, Jiang Q, Pang G, et al. Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice. Neuropharmacology. 2016; 101:246-54. [DOI:10.1016/j.neuropharm.2015.09.031] [PMID]
34. Zarrindast MR, Gholami A, Sahraei H, Haeri-Rohani A. Role of nitric oxide in the acquisition and expression of apomorphine- or morphine-induced locomotor sensitization. Eur J Pharmacol. 2003; 482(1-3):205-13. [DOI:10.1016/j.ejphar.2003.10.006] [PMID]
35. de Graaf R, Bijl RV, Spijker J, Beekman AT, Vollebergh WA. Temporal sequencing of lifetime mood disorders in relation to comorbid anxiety and substance use disorders--findings from the Netherlands Mental Health Survey and Incidence Study. Soc Psychiatry Psychiatr Epidemiol. 2003; 38(1):1-11. [DOI:10.1007/s00127-003-0597-4] [PMID]
36. Sherwood Brown E, Suppes T, Adinoff B, Rajan Thomas N. Drug abuse and bipolar disorder: Comorbidity or misdiagnosis? J Affect Disord. 2001; 65(2):105-15. [DOI:10.1016/S0165-0327(00)00169-5] [PMID]
37. Preston KL, Epstein DH. Stress in the daily lives of cocaine and heroin users: relationship to mood, craving, relapse triggers, and cocaine use. Psychopharmacology (Berl). 2011; 218(1):29-37. [DOI:10.1007/s00213-011-2183-x] [PMID]
38. Sinha R. The role of stress in addiction relapse. Curr Psychiatry Rep. 2007; 9(5):388-95. [DOI:10.1007/s11920-007-0050-6] [PMID]
39. Van Zundert RM, Ferguson SG, Shiffman S, Engels R. Dynamic effects of craving and negative affect on adolescent smoking relapse. Health Psychol. 2012; 31(2):226-34. [DOI:10.1037/a0025204] [PMID]
40. Nunez C, Földes A, Laorden ML, Milanes MV, Kovács KJ. Activation of stress-related hypothalamic neuropeptide gene expression during morphine withdrawal. J Neurochem. 2007; 101(4):1060-71. [DOI:10.1111/j.1471-4159.2006.04421.x] [PMID]
41. Fatseas M, Denis C, Massida Z, Verger M, Franques-Rénéric P, Auriacombe M. Cue-induced reactivity, cortisol response and substance use outcome in treated heroin dependent individuals. Biol Psychiatry. 2011; 70(8):720-27. [DOI:10.1016/j.biopsych.2011.05.015] [PMID]
42. Bearn J, Buntwal N, Papadopoulos A, Checkley S. Salivary cortisol during opiate dependence and withdrawal. Addict Biol. 2001; 6(2):157-62. [DOI:10.1080/13556210020040235] [PMID]
43. Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008; 27(3):49-65. [DOI:10.1080/10550880802122646] [PMID]
44. Taylor CC, Soong YI, Wu D, Yee JS, Szeto HH. Morphine stimulates adrenocorticotropin and cortisol release in the late-term ovine fetus. Pediatr Res. 1997; 41(3):411-5. [DOI:10.1203/00006450-199703000-00018] [PMID]
45. Fan J, Zhang K, Jin Y, Li B, Gao S, Zhu J, Cui R. Pharmacological effects of berberine on mood disorders. J Cell Mol Med. 2019; 23(1):21-8. [DOI:10.1111/jcmm.13930] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2008-1375
pISSN: 1735-7799
Email: journal[at]muq.ac.ir
j.mua.ac[at]gmail.com
